Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study

Philippe Ruszniewski, Juan W Valle, Catherine Lombard-Bohas, Daniel J Cuthbertson, Petros Perros, Luboš Holubec, Gianfranco Delle Fave, Denis Smith, Patricia Niccoli, Pascal Maisonobe, Philippe Atlan, Martyn E Caplin, SYMNET study group

Research output: Contribution to journalArticlepeer-review


BACKGROUND: Lanreotide Autogel/Depot effectively controls symptoms in patients with carcinoid syndrome associated with neuroendocrine tumours. Data on patient-reported outcomes are sparse.

AIM: To evaluate the effect of lanreotide on patient-reported outcomes (PROs) with carcinoid syndrome.

METHODS: This was an international, open-label, observational study of adults with neuroendocrine tumours and history of diarrhoea, receiving lanreotide for >3 months for relief of carcinoid syndrome symptoms. The primary PRO measure was satisfaction with diarrhoea control. Secondary PRO measures included severity, change in symptoms and impact on daily life of diarrhoea; and patient satisfaction with flushing control.

RESULTS: Of 273 patients enrolled, 76% were 'completely' or 'rather' satisfied with diarrhoea control; 79% reported improvement in diarrhoea with lanreotide. The proportion of patients with 'mild', 'minimal', or 'no diarrhoea' increased from 33% before treatment to 75% during treatment; 75% were unconcerned about the impact of diarrhoea on daily life. Satisfaction with flushing control amongst patients with significant flushing at treatment initiation was 73%.

CONCLUSIONS: Lanreotide treatment was associated with improvements in symptoms as well as a range of PROs in patients with neuroendocrine tumours and carcinoid syndrome ( NCT01234168).

Original languageEnglish
Pages (from-to)552-8
Number of pages7
JournalDigestive and Liver Disease
Issue number5
Publication statusPublished - May 2016


  • Adult
  • Aged
  • Antineoplastic Agents
  • Delayed-Action Preparations
  • Diarrhea
  • Female
  • Flushing
  • Humans
  • Internationality
  • Male
  • Malignant Carcinoid Syndrome
  • Middle Aged
  • Patient Reported Outcome Measures
  • Patient Satisfaction
  • Peptides, Cyclic
  • Prospective Studies
  • Somatostatin
  • Journal Article
  • Multicenter Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study'. Together they form a unique fingerprint.

Cite this